Three authors reply [2]

American Journal of Epidemiology

Volumn 164, Issue 2, 2006, Pages 195-196

  Navas Acien, Ana ^a   Sharrett, A Richey ^a   Guallar, Eliseo ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; DRINKING WATER;

ARSENIC POISONING; BEER; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; EPIDEMIC; FOOD CONTAMINATION; HEART FAILURE; HUMAN; LETTER; LONG TERM EXPOSURE; NONHUMAN; SYSTEMATIC REVIEW;

EID: 33745596792     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwj198     Document Type: Letter

References (20)

1. Klatsky AL. Re: "Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence." (Letter). Am J Epidemiol 2006;164:194-5.
2. Navas-Acien A, Sharrett AR, Silbergeld EK, et al. Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am J Epidemiol 2005;162:1037-49.
3. Reynolds ES. An account of the epidemic outbreak of arsenical poisoning occurring in beer drinkers in the north of England and the midland counties in 1900. Lancet 1901;i:166-70.
4. Brunton TL. The action of arsenic as observed during the recent epidemic of arsenic poisoning. Lancet 1901;i:1257-60.
5. Navas-Acien A, Silbergeld EK, Sharrett R, et al. Metals in urine and peripheral arterial disease. Environ Health Perspect 2005;113:164-9.
6. Bradford Hill A, Faning EL. Studies in the incidence of cancer in a factory handling inorganic compounds of arsenic. Mortality experience in the factory. Br J Ind Med 1948;5:1-6.
7. Suspected poisoning by arsenic in beer at Halifax. Lancet 1902;159:385.
8. Edge JR. Myocardial fibrosis following arsenical therapy: report of a case. Lancet 1946;248:675-7.
9. Leng-Levy J, Aubertin J, Leng B, et al. Myocardial involvement in the course of industrial arsenic poisoning. (In French). Bull Mem Soc Med Hop Paris 1968;119:519-26.
10. Zaldivar R. A morbid condition involving cardio-vascular, broncho-pulmonary, digestive and neural lesions in children and young adults after dietary arsenic exposure. Zentralbl Bakteriol [B] 1980;170:44-56.
11. Albores A, Cebrian ME, Tellez I, et al. Comparative study of chronic hydroarsenicalism in 2 rural communities of the Laguna region of Mexico. (In Spanish). Bol Oficina Sanit Panam 1979;86:196-205.
12. Cebrian ME, Albores A, Aguilar M, et al. Chronic arsenic poisoning in the north of Mexico. Hum Toxicol 1983;2:121-33.
13. Frustaci A, Magnavita N, Chimenti C, et al. Marked elevation of myocardial trace elements in idiopathic dilated cardiomyopathy compared with secondary cardiac dysfunction. J Am Coll Cardiol 1999;33:1578-83.
14. Tseng WP. Blackfoot disease in Taiwan: a 30-year follow-up study. Angiology 1989;40:547-58.
15. Xia Y, Liu J. An overview on chronic arsenism via drinking water in PR China. Toxicology 2004;198:25-9.
16. Grinspan D, Biagini R. Chronic endemic regional hydroarsenicism. The manifestations of arsenic poisoning caused by drinking water. (In Spanish). Med Cutan Ibero Lat Am 1985;13:85-109.
17. Li Y, Sun X, Wang L, et al. Myocardial toxicity of arsenic trioxide in a mouse model. Cardiovasc Toxicol 2002;2:63-73.
18. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005;23:2396-410.
19. Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001;97:1514-16.
20. Unnikrishnan D, Dutcher JP, Garl S, et al. Cardiac monitoring of patients receiving arsenic trioxide therapy. Br J Haematol 2004;124:610-17.